• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

已确诊冠心病或风险等同情况且低密度脂蛋白胆固醇得到控制的患者中低高密度脂蛋白胆固醇的患病率。

Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol.

作者信息

Alsheikh-Ali Alawi A, Lin Jen-Liang, Abourjaily Paul, Ahearn Dineli, Kuvin Jeffrey T, Karas Richard H

机构信息

Division of Cardiology and Molecular Cardiology Research Institute, Department of Medicine, Tufts-New England Medical Center and Tufts University School of Medicine, Boston, Massachusetts, USA.

出版信息

Am J Cardiol. 2007 Nov 15;100(10):1499-501. doi: 10.1016/j.amjcard.2007.06.058. Epub 2007 Sep 27.

DOI:10.1016/j.amjcard.2007.06.058
PMID:17996508
Abstract

Current guidelines identify low-density lipoprotein (LDL) cholesterol as the primary target for cardiovascular prevention but also recognize low high-density lipoprotein (HDL) cholesterol as an important secondary target. This study was conducted to determine the prevalence of low HDL cholesterol in a contemporary ambulatory high-risk population across various LDL cholesterol levels, including patients taking statins. Screening of 44,052 electronic medical records from a primary care practice identified 1,512 high-risk patients with documented coronary heart disease (CHD) or CHD risk equivalents. Low HDL cholesterol (< or =40 mg/dl in men, < or =50 mg/dl in women) was present in 66% of the 1,512 patients. Low HDL cholesterol was prevalent across all LDL cholesterol levels but most prevalent in patients with LDL cholesterol < or =70 mg/dl (79% vs 66% in those with LDL cholesterol 71 to 100 mg/dl and 64% in patients with LDL cholesterol >100 mg/dl, p <0.01). Low HDL cholesterol was equally and highly prevalent in patients taking statins (67%) and those not taking statins (64%) (p = NS). HDL cholesterol and LDL cholesterol levels correlated poorly (R(2) = 0.01), and this was unaffected by gender or statin treatment. In conclusion, in high-risk patients with CHD or CHD risk equivalents, low HDL cholesterol levels remain prevalent despite statin treatment and the achievement of aggressive LDL cholesterol goals.

摘要

当前指南将低密度脂蛋白(LDL)胆固醇确定为心血管疾病预防的主要目标,但也认可低高密度脂蛋白(HDL)胆固醇是重要的次要目标。本研究旨在确定在当代门诊高危人群中,不同LDL胆固醇水平(包括服用他汀类药物的患者)下低HDL胆固醇的患病率。对一家初级保健机构的44,052份电子病历进行筛查,确定了1,512名有冠心病(CHD)或CHD风险等同情况记录的高危患者。在这1,512名患者中,66%存在低HDL胆固醇(男性<或=40mg/dl,女性<或=50mg/dl)。低HDL胆固醇在所有LDL胆固醇水平中均普遍存在,但在LDL胆固醇<或=70mg/dl的患者中最为普遍(79%,而LDL胆固醇为71至100mg/dl的患者中为66%,LDL胆固醇>100mg/dl的患者中为64%,p<0.01)。服用他汀类药物的患者(67%)和未服用他汀类药物的患者(64%)中,低HDL胆固醇的患病率同样很高且相当(p=无显著性差异)。HDL胆固醇和LDL胆固醇水平相关性较差(R²=0.01),且不受性别或他汀类药物治疗的影响。总之,在患有CHD或CHD风险等同情况的高危患者中,尽管进行了他汀类药物治疗并实现了积极的LDL胆固醇目标,但低HDL胆固醇水平仍然普遍存在。

相似文献

1
Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol.已确诊冠心病或风险等同情况且低密度脂蛋白胆固醇得到控制的患者中低高密度脂蛋白胆固醇的患病率。
Am J Cardiol. 2007 Nov 15;100(10):1499-501. doi: 10.1016/j.amjcard.2007.06.058. Epub 2007 Sep 27.
2
Extent to which accepted serum lipid goals are achieved in a contemporary general medical population with coronary heart disease risk equivalents.在当代患有冠心病风险等同症的普通医疗人群中,已接受的血清脂质目标的达成程度。
Am J Cardiol. 2006 Nov 1;98(9):1231-3. doi: 10.1016/j.amjcard.2006.05.057. Epub 2006 Sep 7.
3
Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals.脂质治疗评估项目2:一项评估实现低密度脂蛋白胆固醇目标的患者比例的跨国调查。
Circulation. 2009 Jul 7;120(1):28-34. doi: 10.1161/CIRCULATIONAHA.108.838466. Epub 2009 Jun 22.
4
Cholesterol and coronary events. The current thinking.胆固醇与冠心病事件。当前的观点。
Postgrad Med. 2003 Apr;113(4 Suppl):5-14. doi: 10.3810/pgm.04.2003.suppl26.135.
5
Risk determination of dyslipidemia in populations characterized by low levels of high-density lipoprotein cholesterol.以高密度脂蛋白胆固醇水平低为特征的人群中血脂异常的风险判定
Am Heart J. 2003 Dec;146(6):1052-9. doi: 10.1016/S0002-8703(03)00516-7.
6
Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin.依折麦布在无法耐受他汀类药物或尽管服用他汀类药物仍无法达到低密度脂蛋白胆固醇目标的患者中的作用。
Curr Med Res Opin. 2007 Sep;23(9):2183-92. doi: 10.1185/030079907X226267.
7
Distribution of lipid phenotypes in community-living men with coronary heart disease. High prevalence of isolated low levels of high-density lipoprotein cholesterol.社区居住的冠心病男性患者脂质表型的分布。孤立性高密度脂蛋白胆固醇水平低的高患病率。
Arch Intern Med. 1992 Dec;152(12):2412-6.
8
Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2.血脂异常女性低密度脂蛋白胆固醇和高密度脂蛋白胆固醇目标达成情况:脂质治疗评估项目(L-TAP)2
Am Heart J. 2009 Nov;158(5):860-6. doi: 10.1016/j.ahj.2009.08.009.
9
Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.普伐他汀对2073例低密度脂蛋白胆固醇和高密度脂蛋白胆固醇水平均较低患者冠状动脉事件的影响:LIPID研究结果
Eur Heart J. 2004 May;25(9):771-7. doi: 10.1016/j.ehj.2004.03.013.
10
Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.通过升高高密度脂蛋白胆固醇降低心血管风险:烟酸的作用——欧洲高密度脂蛋白胆固醇共识小组制定的立场文件
Curr Med Res Opin. 2004 Aug;20(8):1253-68. doi: 10.1185/030079904125004402.

引用本文的文献

1
Fenofibrate to prevent amputation and reduce vascular complications in patients with diabetes: FENO-PREVENT.非诺贝特预防糖尿病患者截肢和减少血管并发症:FENO-PREVENT。
Cardiovasc Diabetol. 2024 Sep 3;23(1):329. doi: 10.1186/s12933-024-02422-9.
2
Linking elevated HbA1c with atherogenic lipid profile among high risk cardiovascular patients at Qassim, Saudi Arabia.沙特阿拉伯卡西姆地区高危心血管疾病患者中糖化血红蛋白(HbA1c)升高与致动脉粥样硬化血脂谱的关联。
Bioinformation. 2024 Mar 31;20(3):212-216. doi: 10.6026/973206300200212. eCollection 2024.
3
Cannabis and tramadol addiction: Do they imply additive risk for acute myocardial infarction in adults younger than 45 years?
大麻和曲马多成瘾:对于 45 岁以下成年人来说,它们是否意味着急性心肌梗死的风险增加?
Anatol J Cardiol. 2020 Nov;24(5):316-325. doi: 10.14744/AnatolJCardiol.2020.67206.
4
Cardiovascular risk profile of patients with atherogenic dyslipidemia in middle age Lithuanian population.中年立陶宛人群中具有动脉粥样硬化性血脂异常患者的心血管风险特征。
Lipids Health Dis. 2018 Sep 5;17(1):208. doi: 10.1186/s12944-018-0851-0.
5
Relationship of high-density lipoprotein cholesterol with periprocedural myocardial injury following elective percutaneous coronary intervention in patients with low-density lipoprotein cholesterol below 70 mg/dL.低密度脂蛋白胆固醇低于70mg/dL的患者在择期经皮冠状动脉介入治疗后高密度脂蛋白胆固醇与围手术期心肌损伤的关系
J Am Heart Assoc. 2015 Jan 8;4(1):e001412. doi: 10.1161/JAHA.114.001412.
6
Paradoxical negative HDL cholesterol response to atorvastatin and simvastatin treatment in Chinese type 2 diabetic patients.中国2型糖尿病患者对阿托伐他汀和辛伐他汀治疗出现矛盾性高密度脂蛋白胆固醇阴性反应。
Rev Diabet Stud. 2013 Summer-Fall;10(2-3):213-22. doi: 10.1900/RDS.2013.10.213. Epub 2013 Aug 10.
7
Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia?他汀类药物与贝特类药物联合治疗能否预防患有致动脉粥样硬化性混合血脂异常的糖尿病患者发生心血管疾病?
Rev Diabet Stud. 2013 Summer-Fall;10(2-3):171-90. doi: 10.1900/RDS.2013.10.171. Epub 2013 Aug 10.
8
Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.残余心血管风险的分子来源、临床信号及创新解决方案:与亚临床疾病、治疗不足及依从性差的关系:新证据对优化心血管疾病患者预后的影响
Vasc Health Risk Manag. 2013;9:617-70. doi: 10.2147/VHRM.S37119. Epub 2013 Oct 21.
9
Biomarkers and sustainable innovation in cardiovascular drug development: lessons from near and far afield.生物标志物与心血管药物研发中的可持续创新:来自近域和远域的经验教训。
Curr Atheroscler Rep. 2013 May;15(5):321. doi: 10.1007/s11883-013-0321-0.
10
HDL cholesterol and cardiovascular outcomes: what is the evidence?高密度脂蛋白胆固醇与心血管结局:有何证据?
Curr Cardiol Rep. 2013 Apr;15(4):349. doi: 10.1007/s11886-013-0349-3.